Hydrochloric Acid

Hydrochloric Acid

SCHEMBL866127

CCc1cc2c(cc1CC)CC(N)C2.Cl

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 known ✓ P00918 3/20 0.44
DRD2 known ✓ P14416 2/20 0.34
DRD3 known ✓ P35462 2/20 0.34
ACHE known ✓ P22303 2/20 0.34
GRIN2D known ✓ O15399 1/20 0.32
GRIN3B known ✓ O60391 1/20 0.32
GRIN1 known ✓ Q05586 1/20 0.32
GRIN2A known ✓ Q12879 1/20 0.32
GRIN2B known ✓ Q13224 1/20 0.32
GRIN2C known ✓ Q14957 1/20 0.32
GRIN3A known ✓ Q8TCU5 1/20 0.32
ADRB2 known ✓ P07550 1/20 0.31
ADRB1 known ✓ P08588 1/20 0.31
FYN P06241 2/20 0.48
CA1 P00915 3/20 0.44
CA12 O43570 2/20 0.41
CA7 P43166 2/20 0.41
CA14 Q9ULX7 2/20 0.41
MAPT P10636 2/20 0.36
NFKB1 P19838 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29405454 1.00 FYN (0.48) FYNCA1CA2CA12CA7
SCHEMBL29406232 0.98 FYN (0.50) FYNCA1CA2CA12CA7
SCHEMBL614525 0.98 FYN (0.50) FYNCA1CA2CA12CA7
SCHEMBL15630255 0.88 FYN (0.42) FYNCA1CA2CA12CA7
SCHEMBL22504662 0.84 MAPT (0.58) MAPTNFKB1THPOHIF1AHSD17B10
SCHEMBL13072957 0.79 FYN (0.38) FYNDRD3GRIN2DGRIN3BGRIN1
SCHEMBL20443999 0.74 FYN (0.33) FYNDRD3GRIN2DGRIN3BGRIN1
SCHEMBL17513822 0.74 FYN (0.33) FYNMAPTHSD17B10ALDH1A1KDM4E
SCHEMBL17949696 0.74 FYN (0.38) FYNMAPTHSD17B10ALDH1A1KDM4E
SCHEMBL29653964 0.74 FYN (0.38) FYNMAPTHSD17B10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116239474-A Preparation method of indacaterol intermediate 5, 6-diethyl-2, 3-dihydro-1H-indene-2-amine hydrochloride 石家庄手性化学有限公司 2023-06-09 CN claimed
CN-115925623-A Small molecule inhibitor and preparation method and application thereof 中国药科大学 2023-04-07 CN claimed
CN-115636784-A LYW-1 derivative and preparation method and application thereof 中国药科大学 2023-01-24 CN claimed
CN-115251078-A Faint scent type insecticide and preparation method thereof 安徽朗宜百草生物工程有限公司 2022-11-01 CN claimed
CN-114698642-A Fragrant insecticide and preparation method thereof 安徽朗宜百草生物工程有限公司 2022-07-05 CN claimed
CN-110183330-B Preparation method of 5, 6-diethyl-2, 3-dihydro-1H-indene-2-amine hydrochloride 安徽华邦药业有限公司 2022-05-27 CN claimed
EP-1487781-B8 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2009-06-03 EP claimed
US-6933410-B2 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2005-08-23 US claimed
EP-1487781-A2 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES Novartis AG (CH) 2004-12-22 EP claimed
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2003-10-02 US claimed
WO-2003076387-A2 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2003-09-18 WO claimed
CN-116239474-A Preparation method of indacaterol intermediate 5, 6-diethyl-2, 3-dihydro-1H-indene-2-amine hydrochloride 石家庄手性化学有限公司 2023-06-09 CN disclosed
CN-116239474-A Preparation method of indacaterol intermediate 5, 6-diethyl-2, 3-dihydro-1H-indene-2-amine hydrochloride 石家庄手性化学有限公司 2023-06-09 CN disclosed
CN-116239474-A Preparation method of indacaterol intermediate 5, 6-diethyl-2, 3-dihydro-1H-indene-2-amine hydrochloride 石家庄手性化学有限公司 2023-06-09 CN disclosed
CN-115925623-A Small molecule inhibitor and preparation method and application thereof 中国药科大学 2023-04-07 CN disclosed
WO-2004096800-A2 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS NOVARTIS AG (CH) 2004-11-11 WO disclosed
US-6800643-B2 CORTICOSTEROID AND AN INDANYL-QUINOLINONE COMPOUND NOVARTIS AG (CH) 2004-10-05 US disclosed
US-20040038951-A1 Organic compounds NOVARTIS AG (CH) 2004-02-26 US disclosed
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NOVARTIS AG (CH) 2003-10-02 US disclosed
WO-2003076387-A2 PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES NOVARTIS AG (CH) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038951-A1 Organic compounds CYP11B2, NR3C2, CYP11B1 CA2 618/4885DRD2 3211/4885DRD3 2591/4885
US-20030187301-A1 Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine NAT1, AADAC, IDH3A CA2 1591/4885DRD2 80/4885DRD3 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.